ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the results from its REACH PVI study were presented at the New Cardiovascular Horizons (NCVH) Conference. This study prospectively […]
Other News
Caladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors
BASKING RIDGE, N.J., July 28, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced the appointment of Michael H. Davidson, MD to its Board of Directors. […]
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data
MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ — CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Data Monitoring Committee (DMC) of the REFRESH 2-AKI trial has completed a comprehensive favorable review […]
A startup that monitors heart health with a toilet seat joins Innovators’ Network
Heart Health Intelligence is the latest member of the American Heart Association’s Center for Health Technology & Innovation Innovators’ Network ROCHESTER, N.Y., July 28, 2020 (GLOBE NEWSWIRE) — Heart Health Intelligence (HHI) has joined the American Heart Association’s Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and […]
Sequana Medical announces €7.3 million debt financing and provides clinical update
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 28 July 2020, 07:00 CEST Cash runway extended into H2 2021 enabling Sequana Medical to reach key near term value inflection points POSEIDON – implants resumed and interim results expected in Q1 2021 (North American pivotal study of the alfapump® in patients with recurrent or […]
Stratus™ Now Offers In-Network Coverage for Veterans
Partnership with Optum and TriWest Brings Affordable Care Through the VA DALLAS, July 28, 2020 /PRNewswire/ — Stratus, the nation’s leading provider of in-home video EEG testing and monitoring services, announced today it has received in-network status to provided services to Veterans through Optum Public Sector Solutions, Inc. (Optum), a subsidiary of […]
Cerus Endovascular Receives CE Mark Approval for its CerusEndo MC 021 Microcatheter
Commercial Sales Across European Union Expected to Begin During Fourth Quarter of 2020 FREMONT, Calif. and OXFORD, United Kingdom, July 28, 2020 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its state of the art CerusEndo MC 021 microcatheter, designed to […]
Rapid Medical Receives CE Mark for TIGERTRIEVER™ XL
TIGERTRIEVER XL is the largest stentriever available, designed to safely remove clots from intracranial vessels up to 9mm in diameter YOKNEAM, Israel, July 27, 2020 /PRNewswire/ — Rapid Medical, a company focused on the development of next generation neurovascular devices, has announced that it received CE Mark for TIGERTRIEVER XL. In addition, the first […]
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announced that an investigator initiated study, authored by Dr. Samir Awad, Professor of Surgery at Baylor College of Medicine, entitled ‘The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients […]
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) Prevention
VASCEPA showed significant reduction in coronary revascularization, including coronary stenting and cardiac bypass surgery, in prespecified and post hoc analyses of landmark REDUCE-IT study First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses, with results consistent across different types […]



